The U.K. Medicines and Healthcare Regulatory Agency (MHRA)has green-lighted two separate Phase 3 trials conducted byCompass Pathways(NASDAQ:CMPS) for Treatment-Resistant Depression andAwakn Life Sciences(OTC:AWKNF) for Severe Alcohol Use Disorder (SAUD).

Details On Trials

Compass Pathways plc (NASDAQ:CMPS) will initiate the UK arm of its Phase 3 program on psilocybin therapy COMP360 for Treatment-Resistant Depression (TRD).

The ongoing program is reportedly the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. It consists of two pivotal trials, COMP 005 and COMP 006, each with an integrated long-term outcomes component.

Following the MHRA...